Comprehensive information about experimentally validated enhancers
| Enhancer ID: | E_04004 |
| Species: | Homo sapiens |
| Position : | chr19:15308673-15308842 |
| Year: | 2019 |
| Title: | Eradication of Central Nervous System Leukemia of T-Cell Origin with a Brain-Permeable LSD1 Inhibitor. |
| Genome Build: | hg19 |
| Enhancer Type: | Super-enhancer |
| Condition: | Disease |
| Disease Name: | Central Nervous System Leukemia |
| PMID: | 30518632 |
| Tissue: | blood / hematopoietic system |
| Tissue Ontology ID: | UBERON:0000178 |
| Cell Source: | T-acute lymphoblastic leukemia (T-ALL) |
| Cell Type: | malignant cell |
| Cell Ontology ID: | CL:0001064 |
| Experiment Type: | TF-binding/chromatin assay; In vivo functional validation; Disease-associated enhancer analysis |
| Low Throughput Method: | ChIP-qPCR/ChIP; RT-qPCR/qPCR; Transgenic/LacZ assay |
| Target gene : | NOTCH3 |
| TF name : | ZEB2 |
| Regulatory State : | Repressed |
| GeneName | Pathway Name | Source | Gene Number |
|---|---|---|---|
| ZEB2 | TGF_beta_Receptor | netpath | 220 |